"Velcro" engineering of high affinity CD47 Ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis

Journal of Biological Chemistry

Volumn 290, Issue 20, 2015, Pages 12650-12663

  Ho, Chia Chi M ^a,b   Guo, Nan ^b   Sockolosky, Jonathan T ^b   Ring, Aaron M ^b   Weiskopf, Kipp ^b   Özkan, Engin ^b   Mori, Yasuo ^b,c   Weissman, Irving L ^b,c   Garcia, K Christopher ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BIOCHEMISTRY; CELL MEMBRANES; CELLS; CYTOLOGY; IMMUNOLOGY; MACROPHAGES; MOBILE SECURITY; MONOCLONAL ANTIBODIES; PROTEINS; TISSUE ENGINEERING; TUMORS;

AFFINITY MATURATION; BINDING INTERFACE; CANCER IMMUNOTHERAPY; CELL SURFACE PROTEINS; HUMAN MACROPHAGES; PROTEIN ENGINEERING; SIGNAL REGULATORY PROTEINS; TISSUE EXPRESSION;

ANTIBODIES;

ANTIBODY; CD47 ANTIGEN; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD47 PROTEIN, HUMAN; CD47 PROTEIN, MOUSE; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN RECEPTOR; PROTEIN BINDING; PTPNS1 PROTEIN, MOUSE; SIRPA PROTEIN, HUMAN;

ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BONE MARROW CELL; CELL PHAGOCYTOSIS; ERYTHROID CELL; HUMAN; HUMAN CELL; LYMPHOID CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; VELCRO ENGINEERING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENETICS; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; PHAGOCYTOSIS; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MICE; NEOPLASMS; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IMMUNOLOGIC;

EID: 84929347431     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.648220     Document Type: Article

References (61)

1. Wynn, T. A., Chawla, A., and Pollard, J. W. (2013) Macrophage biology in development, homeostasis and disease. Nature 496, 445-455
2. Lewis, C. E., and Pollard, J. W. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612
3. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., Torigian, D. A., O'Dwyer, P. J., and Vonderheide, R. H. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616
4. Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., and Majeti, R. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384
5. Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., Park, C. Y., Zhao, F., Kohrt, H. E., Malumbres, R., Briones, J., et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713
6. Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., and Weissman, I. L. (2011) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118, 4890-4901
7. Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J. P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., Beck, A. H., Weissman, I. L., and van de Rijn, M. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. U.S.A. 109, 6656-6661
8. Houot, R., Kohrt, H. E., Marabelle, A., and Levy, R. (2011) Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol. 32, 510-516
9. Oldenborg, P. A., Zheleznyak, A., Fang, Y. F., Lagenaur, C. F., Gresham, H. D., and Lindberg, F. P. (2000) Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054
10. Tsai, R. K., and Discher, D. E. (2008) Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180, 989-1003
11. Oldenborg, P. A., Gresham, H. D., and Lindberg, F. P. (2001) CD47-signal regulatory protein α (SIRPα) regulates Fcγ and complement receptor-mediated phagocytosis. J. Exp. Med. 193, 855-862
12. Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., Birnbaum, D., van Elsas, A., Kuijpers, T. W., Bertucci, F., and van den Berg, T. K. (2011) CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. U.S.A. 108, 18342-18347
13. Jaiswal, S., Jamieson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., and Weissman, I. L. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285
14. Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., Jr., van Rooijen, N., and Weissman, I. L. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299
15. Brown, E. J., and Frazier, W. A. (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11, 130-135
16. Adams, S., van der Laan, L. J., Vernon-Wilson, E., Renardel de Lavalette, C., Döpp, E. A., Dijkstra, C. D., Simmons, D. L., and van den Berg, T. K. (1998) Signal regulatory protein is selectively expressed by myeloid and neuronal cells. J. Immunol. 161, 1853-1859
17. Takenaka, K., Prasolava, T. K., Wang, J. C., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E., and Danska, J. S. (2007) Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 8, 1313-1323
18. Liu, Y., Tong, Q., Zhou, Y., Lee, H. W., Yang, J. J., Bühring, H. J., Chen, Y. T., Ha, B., Chen, C. X., Yang, Y., and Zen, K. (2007) Functional elements on SIRPα IgV domain mediate cell surface binding to CD47. J. Mol. Biol. 365, 680-693
19. Hatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I., and Barclay, A. N. (2008) Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol. Cell 31, 266-277
20. Veillette, A., Thibaudeau, E., and Latour, S. (1998) High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J. Biol. Chem. 273, 22719-22728
21. Willingham, S. B., Volkmer, J. P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., Lovelace, P., Scheeren, F. A., Chao, M. P., Weiskopf, K., Tang, C., et al. (2012) The CD47-signal regulatory proteinα (SIRPα) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 6662-6667
22. Weiskopf, K., Ring, A. M., Ho, C. C., Volkmer, J. P., Levin, A. M., Volkmer, A. K., Ozkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., and Garcia, K. C. (2013) Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88-91
23. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220-233
24. Gibson, D. G., Young, L., Chuang, R. Y., Venter, J. C., Hutchison, C. A., 3rd, and Smith, H. O. (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343-345
25. Hatherley, D., Lea, S. M., Johnson, S., and Barclay, A. N. (2014) Polymorphisms in the human inhibitory signal regulatory protein α do not affect binding to its ligand CD47. J. Biol. Chem. 289, 10024-10028
26. Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., Ozkan, E., Davis, M. M., Wucherpfennig, K. W., and Garcia, K. C. (2014) Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-1087
27. Boder, E. T., and Wittrup, K. D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557\
28. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
29. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography &NMRsystem: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921
30. Brunger, A. T. (2007) Version 1.2 of the Crystallography andNMR system. Nat. Protoc. 2, 2728-2733
31. Mori, Y., Iwasaki, H., Kohno, K., Yoshimoto, G., Kikushige, Y., Okeda, A., Uike, N., Niiro, H., Takenaka, K., Nagafuji, K., Miyamoto, T., Harada, M., Takatsu, K., and Akashi, K. (2009) Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J. Exp. Med. 206, 183-193
32. Chen, J., Sawyer, N., and Regan, L. (2013) Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci. 22, 510-515
33. Lamminmäki, U., Paupério, S., Westerlund-Karlsson, A., Karvinen, J., Virtanen, P. L., Lövgren, T., and Saviranta, P. (1999) Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies. J. Mol. Biol. 291, 589-602
34. Lee, C. V., Liang, W. C., Dennis, M. S., Eigenbrot, C., Sidhu, S. S., and Fuh, G. (2004) High affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 340, 1073-1093
35. Boder, E. T., and Wittrup, K. D. (1998) Optimal screening of surface-displayed polypeptide libraries. Biotechnol. Prog. 14, 55-62
36. Miyauchi, S., Gopal, E., Babu, E., Srinivas, S. R., Kubo, Y., Umapathy, N. S., Thakkar, S. V., Ganapathy, V., and Prasad, P. D. (2010) Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Biochim. Biophys. Acta 1798, 1164-1171
37. Ganapathy, V., Roesel, R. A., Howard, J. C., and Leibach, F. H. (1983) Interaction of proline, 5-oxoproline, and pipecolic acid for renal transport in the rabbit. J. Biol. Chem. 258, 2266-2272
38. Strowig, T., Rongvaux, A., Rathinam, C., Takizawa, H., Borsotti, C., Philbrick, W., Eynon, E. E., Manz, M. G., and Flavell, R. A. (2011) Transgenic expression of human signal regulatory protein α in Rag2-/-γ (c)-/-mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl. Acad. Sci. U.S.A. 108, 13218-13223
39. Barclay, A. N., and Van den Berg, T. K. (2014) The interaction between signal regulatory protein α (SIRPα) and CD47: structure, function, and therapeutic target. Annu. Rev. Immunol. 32, 25-50
40. Ide, K., Wang, H., Tahara, H., Liu, J., Wang, X., Asahara, T., Sykes, M., Yang, Y. G., and Ohdan, H. (2007) Role for CD47-SIRPα signaling in xenograft rejection by macrophages. Proc. Natl. Acad. Sci. U.S.A. 104, 5062-5066
41. Baba, N., Van, V. Q., Wakahara, K., Rubio, M., Fortin, G., Panzini, B., Soucy, G., Wassef, R., Richard, C., Tamaz, R., Lahaie, R., Bernard, E. J., Caussignac, Y., Leduc, R., Lougnarath, R., et al. (2013) CD47 fusion protein targets CD172a+ cells in Crohn's disease and dampens the production of IL-1β and TNF. J. Exp. Med. 210, 1251-1263
42. van der Merwe, P. A., and Dushek, O. (2011) Mechanisms for T cell receptor triggering. Nat. Rev. Immunol. 11, 47-55
43. Wang, H., VerHalen, J., Madariaga, M. L., Xiang, S., Wang, S., Lan, P., Oldenborg, P. A., Sykes, M., and Yang, Y. G. (2007) Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 109, 836-842
44. Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., and Discher, D. E. (2013) Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975
45. Bain, C. C., and Mowat, A. M. (2011) Intestinal macrophages-specialised adaptation to a unique environment. Eur. J. Immunol. 41, 2494-2498
46. Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., Takahashi, K., Holers, V. M., Walport, M., Gerard, C., Ezekowitz, A., Carroll, M. C., Brenner, M., Weissleder, R., Verbeek, J. S., et al. (2002) Arthritis critically dependent on innate immune system players. Immunity 16, 157-168
47. Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184
48. Bhargava, P., and Lee, C. H. (2012) Role and function of macrophages in the metabolic syndrome. Biochem. J. 442, 253-262
49. Weissleder, R., Nahrendorf, M., and Pittet, M. J. (2014) Imaging macrophages with nanoparticles. Nat. Mater. 13, 125-138
50. Desai, N. (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J. 14, 282-295
51. Maack, T., Johnson, V., Kau, S. T., Figueiredo, J., and Sigulem, D. (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16, 251-270
52. Momtaz, P., and Postow, M. A. (2014) Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med. 7, 357-365
53. Peggs, K. S., Quezada, S. A., Korman, A. J., and Allison, J. P. (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206-213
54. Shin, D. S., and Ribas, A. (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33C, 23-35
55. Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., Pande, V. S., Fathman, C. G., Boyman, O., and Garcia, K. C. (2012) Exploiting a natural conformational switch to engineer an interleukin-2 'superkine.' Nature 484, 529-533
56. Junttila, I. S., Creusot, R. J., Moraga, I., Bates, D. L., Wong, M. T., Alonso, M. N., Suhoski, M. M., Lupardus, P., Meier-Schellersheim, M., Engleman, E. G., Utz, P. J., Fathman, C. G., Paul, W. E., and Garcia, K. C. (2012) Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990-998
57. Ring, A. M., Manglik, A., Kruse, A. C., Enos, M. D., Weis, W. I., Garcia, K. C., and Kobilka, B. K. (2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature 502, 575-579
58. Pepper, L. R., Cho, Y. K., Boder, E. T., and Shusta, E. V. (2008) A decade of yeast surface display technology: where are we now? Comb. Chem. High Throughput Screen. 11, 127-134
59. Caoili, S. E. (2012) On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity. Adv. Bioinformatics 2012:346765
60. Poulsen, T. R., Jensen, A., Haurum, J. S., and Andersen, P. S. (2011) Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J. Immunol. 187, 4229-4235
61. Foote, J., and Eisen, H. N. (2000) Breaking the affinity ceiling for antibodies and T cell receptors. Proc. Natl. Acad. Sci. U.S.A. 97, 10679-10681